96 results on '"Sieper, Joachim"'
Search Results
2. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time‐Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From the German Spondyloarthritis Inception Cohort
3. Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
4. MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis
5. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
6. Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
7. Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
8. Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
9. Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal?
10. Sensitivity and Specificity of Autoantibodies Against CD 74 in Nonradiographic Axial Spondyloarthritis
11. Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long‐Term Anti–Tumor Necrosis Factor Treatment: Six‐Year Results of Continuous Treatment With Etanercept
12. Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
13. Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research
14. Effects of Long‐Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104‐Week Results From a Randomized, Placebo‐Controlled Study
15. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies
16. Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al
17. Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis
18. Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Acti
19. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berl
20. Reply
21. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort
22. Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
23. Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression
24. miR‐148a is upregulated by Twist1 and T‐bet and promotes Th1‐cell survival by regulating the proapoptotic gene Bim
25. The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns
26. Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial
27. Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis
28. Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
29. In Situ Analysis of Interleukin-23- and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
30. Loss of methylation at theIFNGpromoter and CNS-1 is associated with the development of functional IFN-γ memory in human CD4+T lymphocytes
31. Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?
32. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?
33. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis
34. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
35. HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: Potential contribution to local immunopathologic processes in ankylosing spondylitis
36. The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort
37. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
38. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period
39. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two
40. Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes
41. From transcriptome to cytome: Integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases
42. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
43. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two–week open-label trial
44. Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria
45. Identification of immunodominant CD4+ T cell epitopes in patients withYersinia-induced reactive arthritis by cytometric cytokine secretion assay
46. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis
47. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone–cartilage interface and subchondral bone marrow
48. HLA–B27–restricted CD8+ T cell response to cartilage‐derived self peptides in ankylosing spondylitis
49. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
50. The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.